Iovance Biotherapeutics, Inc. (IOVA) Financial Statements (2024 and earlier)

Company Profile

Business Address 825 INDUSTRIAL ROAD
SAN CARLOS, CA 94070
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments250,894626,292471,845360,173424,458482,189
Cash and cash equivalents230,010543,484231,731118,366108,07592,360
Short-term investments20,88482,808240,114241,807316,383389,829
Receivables 33     
Inventory, net of allowances, customer advances and progress billings9,720     
Inventory9,720     
Other undisclosed current assets14,23111,4897,2719,7117,1357,779
Total current assets:274,878637,781479,116369,884431,593489,968
Noncurrent Assets
Operating lease, right-of-use asset67,63170,43173,01568,26870,84573,475
Property, plant and equipment112,549109,923105,232100,746101,154102,757
Long-term investments and receivables      27,701
Long-term investments      27,701
Intangible assets, net (including goodwill)235,511     
Intangible assets, net (excluding goodwill)235,511     
Other noncurrent assets2942021895968561,266
Other undisclosed noncurrent assets66,4306,4306,4306,4306,4306,084
Total noncurrent assets:482,415186,986184,866176,040179,285211,283
TOTAL ASSETS:757,293824,767663,982545,924610,878701,251
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities77,77774,66078,89872,07457,70969,365
Accounts payable31,15731,57226,60324,25520,00920,454
Accrued liabilities46,62043,08852,29547,81937,70048,911
Other undisclosed current liabilities10,86612,61412,5877,1716,4837,710
Total current liabilities:88,64387,27491,48579,24564,19277,075
Noncurrent Liabilities
Long-term debt and lease obligation1,0001,0001,00072,94373,99672,184
Long-term debt, excluding current maturities1,0001,0001,0001,0001,0001,000
Liabilities, other than long-term debt89,08169,61271,859   
Deferred income tax liabilities20,237     
Operating lease, liability68,84469,61271,85971,94372,99671,184
Other undisclosed noncurrent liabilities    (71,943)(72,996)(71,184)
Total noncurrent liabilities:90,08170,61272,85972,94373,99672,184
Total liabilities:178,724157,886164,344152,188138,188149,259
Equity
Equity, attributable to parent, including:578,569666,881499,638393,736472,690551,992
Common stock998777
Additional paid in capital2,360,4682,342,7032,068,8671,858,7831,838,7781,818,377
Accumulated other comprehensive income (loss)325(126)(902)(2,038)(2,697)(2,343)
Accumulated deficit(1,782,236)(1,675,708)(1,568,338)(1,463,019)(1,363,401)(1,264,052)
Other undisclosed equity, attributable to parent333333
Total equity:578,569666,881499,638393,736472,690551,992
TOTAL LIABILITIES AND EQUITY:757,293824,767663,982545,924610,878701,251

Income Statement (P&L) ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
Revenues238     
Cost of revenue(2,050)     
Gross profit:(1,812)     
Operating expenses(108,274)(110,856)(107,036)(100,395)(99,734)(91,713)
Operating loss:(110,086)(110,856)(107,036)(100,395)(99,734)(91,713)
Nonoperating income
(Investment Income, Nonoperating)
3,0813,4861,717777385106
Loss from continuing operations before income taxes:(107,005)(107,370)(105,319)(99,618)(99,349)(91,607)
Income tax benefit477     
Loss from continuing operations:(106,528)(107,370)(105,319)(99,618)(99,349)(91,607)
Loss before gain (loss) on sale of properties:(99,618)(99,349)(91,607)
Net loss available to common stockholders, diluted:(106,528)(107,370)(105,319)(99,618)(99,349)(91,607)

Comprehensive Income ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
Net loss:(106,528)(107,370)(105,319)(99,618)(99,349)(91,607)
Comprehensive loss:(106,528)(107,370)(105,319)(99,618)(99,349)(91,607)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent4517761,136659(354)(1,742)
Comprehensive loss, net of tax, attributable to parent:(106,077)(106,594)(104,183)(98,959)(99,703)(93,349)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: